This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Hyundai Pharm Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Seung-Tae Kang: Innovator in GLP-1 Receptor Agonists
Introduction
Seung-Tae Kang is a prominent inventor based in Suwon-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of GLP-1 receptor agonists. His work is crucial in addressing diseases associated with GLP-1 activity.
Latest Patents
Seung-Tae Kang holds a patent for a GLP-1 receptor agonist. The invention relates to a compound represented by Formula 1, wherein A, B, L, X, and R are defined as described in the patent. This compound, or a pharmaceutically acceptable salt thereof, serves as a GLP-1 receptor agonist and may be useful in the prevention or treatment of diseases associated with GLP-1 activity. He has 1 patent to his name.
Career Highlights
Seung-Tae Kang is currently employed at Hyundai Pharm Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has garnered attention for its potential impact on therapeutic strategies.
Collaborations
Some of his notable coworkers include Han Kyu Lee and Jeong-Un Hwang, who contribute to the collaborative efforts in research and development at Hyundai Pharm Co., Ltd.
Conclusion
Seung-Tae Kang is a key figure in the development of GLP-1 receptor agonists, with a focus on innovative solutions for health challenges. His contributions to the field are invaluable and continue to shape the future of pharmaceutical research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile